Moving Forward – Essential Questions for the Next 10 Years

Authors

  • Richard B. Lipton MD,

    1. From the Departments of Neurology, Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (R.B. Lipton and F.D. Sheftell); The Montefiore Headache Center, Bronx, NY (R.B. Lipton); The New England Center for Headache, Stamford, CT, USA (F.D. Sheftell).
    Search for more papers by this author
  • Fred D. Sheftell MD

    1. From the Departments of Neurology, Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (R.B. Lipton and F.D. Sheftell); The Montefiore Headache Center, Bronx, NY (R.B. Lipton); The New England Center for Headache, Stamford, CT, USA (F.D. Sheftell).
    Search for more papers by this author

  • Conflicts of Interest: Drs. Lipton and Sheftell have received research funding from Merck and have acted as paid consultants for Merck.

R.B. Lipton, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Rousso 332, Bronx, NY 10461, USA.

Abstract

The future is bright for migraine sufferers. For acute treatment, CGRP antagonists and combination products will provide more complete, longer lasting, and safer relief. “Designer drugs” for migraine prevention will be identified based on their ability to block cortical spreading depression and will improve migraine treatment. Genetic and environmental risk factors that promote migraine progression will be identified and preventing progression will become a standard goal in treatment. Some of the devices intended to treat migraine will be approved and will provide important options for sufferers seeking to avoid drugs. Clinical trials that evaluate behavioral and pharmacologic interventions and their impact on patient centered outcomes will emerge. The emergence of novel treatments, when coupled with strategies for individualizing and optimizing treatment while maximizing adherence, will result in ever improving patient outcomes.

Ancillary